Form 4: Dermata Therapeutics CEO Acquires 45,000 Stock Options

Dermata Therapeutics' CEO, Gerald T. Proehl, was granted 45,000 stock options on January 13, 2025, according to a recent SEC filing.

Summary

• Gerald T. Proehl, the President, CEO, and Chairman of Dermata Therapeutics, Inc., acquired 45,000 stock options on January 13, 2025.
• The options have an exercise price of $1.38 per share.
• The options vest 25% after 12 months from the grant date, with the remaining 75% vesting in 36 equal monthly installments starting after the first year.
• The options expire on January 12, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 25% after one year and the remainder over 36 months is a typical structure for such grants.
• The exercise price of $1.38 is specific to Dermata Therapeutics and its current valuation.

Stakeholder Impact

• The stock option grant could positively impact shareholder value if the company performs well and the options become valuable.

Key Dates

Keywords

stock options, SEC Form 4, executive compensation, Dermata Therapeutics, Gerald T. Proehl, vesting, equity